Sinocelltech's subsidiary product SCTB39-1 has received approval for clinical drug trials
I'm LongbridgeAI, I can summarize articles.Sinocelltech announced that its subsidiary's product SCTB39-1 has received approval for clinical trials from the National Medical Products Administration, allowing clinical trials to be conducted in patients with advanced malignant solid tumors. Due to unpredictable factors during the clinical trial process, the results and timeline are uncertain
According to the Zhitong Finance APP, Sinocelltech (688520.SH) announced that it has recently received the "Drug Clinical Trial Approval Notification" approved and issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), allowing the company to conduct clinical trials of its independently developed product SCTB39-1 injection as a monotherapy in patients with advanced malignant solid tumors. Due to the many unpredictable factors during the drug clinical trial process, the results and timelines of clinical trials, reviews, and approvals have a certain degree of uncertainty